Enveric Biosciences, Inc. (ENVB)Â
NASDAQ$1.61-0.06 (-3.59%)
Market Cap
$3.21M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
576 of 919
Rank in Industry
334 of 523
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ENVB Insider Trading Activity
ENVB Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
No records found
About Enveric Biosciences, Inc.
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Insider Activity of Enveric Biosciences, Inc.
Over the last 12 months, insiders at Enveric Biosciences, Inc. have bought $0 and sold $0 worth of Enveric Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Enveric Biosciences, Inc. have bought $2,140 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $2,140 was made by PASQUALONE FRANK (director) on 2023‑09‑15.
List of Insider Buy and Sell Transactions, Enveric Biosciences, Inc.
| 2023-09-15 | PASQUALONE FRANK | director | 1,000 0.043% | $2.14 | $2,140 | -59.50% | ||
| 2018-11-16 | Sale | Sikaria Lokesh | 10 percent owner | 100,000 1.778% | $0.30 | $29,550 | -7.42% | |
| 2018-11-16 | Sale | Sikaria Family 2008 Revocable Trust Dated 02/28/2008 | 10 percent owner | 100,000 1.778% | $0.30 | $29,550 | -7.42% | |
| 2018-11-16 | Sale | Sikaria Chanda | 10 percent owner | 100,000 1.778% | $0.30 | $29,550 | -7.42% | |
| 2018-11-16 | Sale | Lokesh Sikaria Trust Dated 12/14/2012 | 10 percent owner | 100,000 1.778% | $0.30 | $29,550 | -7.42% | |
| 2018-07-17 | Sale | Devanur Giri | 10 percent owner | 100,000 2.4059% | $2.27 | $226,630 | -81.01% | |
| 2018-06-07 | Sale | Devanur Giri | 10 percent owner | 329,357 10.2759% | $2.01 | $661,316 | -75.69% | |
| 2017-11-17 | Eberwein Jeffrey E. | 100,000 2.8873% | $4.12 | $411,500 | -59.37% | |||
| 2017-11-17 | Devanur Giri | President & CEO | 12,121 0.35% | $4.12 | $49,878 | -59.37% | ||
| 2017-11-17 | Rai Dhruwa N | director | 145,450 4.1995% | $4.12 | $598,527 | -59.37% | ||
| 2017-10-30 | Eberwein Jeffrey E. | 1,303 0.0319% | $6.50 | $8,469 | -77.77% | |||
| 2017-10-27 | Eberwein Jeffrey E. | 2,500 0.0612% | $6.50 | $16,250 | -77.38% | |||
| 2017-09-06 | Eberwein Jeffrey E. | 7,500 0.2039% | $6.50 | $48,750 | -76.77% | |||
| 2017-08-21 | Eberwein Jeffrey E. | 2,604 0.0672% | $6.50 | $16,924 | -77.96% | |||
| 2017-03-30 | Eberwein Jeffrey E. | 223 0.0063% | $6.51 | $1,452 | -54.84% | |||
| 2017-02-10 | Eberwein Jeffrey E. | 434 0.0123% | $6.51 | $2,825 | -52.69% | |||
| 2017-01-23 | Eberwein Jeffrey E. | 2,130 0.0605% | $6.51 | $13,866 | -48.66% | |||
| 2017-01-18 | Eberwein Jeffrey E. | 10,000 0.2839% | $6.51 | $65,100 | -52.38% | |||
| 2016-12-30 | Eberwein Jeffrey E. | 40 0.0012% | $6.51 | $260 | -52.38% | |||
| 2016-12-29 | Eberwein Jeffrey E. | 706 0.0203% | $6.51 | $4,596 | -53.30% |
Total: 85
Insider Historical Profitability
<0.0001%
| GOTTLIEB JAY | Chief Executive Officer | 4677484 243.3768% | $7.81M | 3 | 0 | |
| Eberwein Jeffrey E. | 2972592 154.6686% | $4.96M | 67 | 0 | ||
| SCHNEIDER GREGGORY A | Chief Financial Officer | 2781766 144.7396% | $4.65M | 3 | 1 | |
| Sikaria Family 2008 Revocable Trust Dated 02/28/2008 | 10 percent owner | 2250000 117.071% | $3.76M | 0 | 1 | |
| Sikaria Chanda | 10 percent owner | 2250000 117.071% | $3.76M | 0 | 1 | |
| Sikaria Lokesh | 10 percent owner | 2250000 117.071% | $3.76M | 0 | 1 | |
| Lokesh Sikaria Trust Dated 12/14/2012 | 10 percent owner | 2250000 117.071% | $3.76M | 0 | 1 | |
| Devanur Giri | 10 percent owner | 1761989 91.6791% | $2.94M | 1 | 2 | |
| MANDELL HENRY R | Chairman/CEO/CFO/Secretary | 651572 33.9023% | $1.09M | 0 | 2 | |
| Rai Dhruwa N | director | 648779 33.757% | $1.08M | 1 | 0 | |
| PASQUALONE FRANK | director | 1000 0.052% | $1,670.00 | 1 | 0 | <0.0001% |
Historical Insider Profitability vs. Competitors
$1,138,733 | 28 | -4.94% | $2.85M | |
$63,749,694 | 24 | -12.24% | $2.58M | |
$193,112 | 22 | -20.59% | $1.64M | |
$1,616,354 | 20 | -12.22% | $3.62M | |
$613,181 | 18 | -20.90% | $2.11M | |
$742,412 | 14 | -50.36% | $1.58M | |
$111,212 | 12 | -28.79% | $3.19M | |
$111,748 | 9 | -47.72% | $3.59M | |
$100,375 | 8 | -51.85% | $3.32M | |
$159,974 | 7 | -18.60% | $3.42M | |
$603,773 | 6 | -56.12% | $3.28M | |
$53,399 | 6 | -70.96% | $1.91M | |
$1,057,000 | 3 | 5.27% | $3.91M | |
$608,453 | 3 | -53.52% | $3.38M | |
$37,465 | 3 | -40.67% | $2.47M | |
$12,240 | 2 | -1.26% | $1.95M | |
$165,600 | 2 | -3.58% | $3.58M | |
Enveric Biosciences, Inc. (ENVB) | $2,140 | 1 | -59.50% | $3.21M |
$739,010 | 1 | 3.33% | $3.52M |
ENVB Institutional Investors: Active Positions
| Increased Positions | 8 | +53.33% | 25,299 | +53.35% |
| Decreased Positions | 4 | -26.67% | 768 | -1.62% |
| New Positions | 3 | New | 2,189 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 19 | +26.67% | 71,952 | +51.73% |
ENVB Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Advisorshares Investments Llc | $70.00 | 2% | 39,992 | +15,521 | +63.43% | 2024-12-31 |
| Geode Capital Management, Llc | $25.00 | 0.72% | 14,440 | -87 | -0.6% | 2024-12-31 |
| Ubs Group Ag | $9.00 | 0.26% | 5,227 | +5,178 | +10,567.35% | 2024-12-31 |
| Virtu Financial Llc | $6.00 | 0.19% | 3,718 | +2,177 | +141.27% | 2024-12-31 |
| Two Sigma Securities, Llc | $4.00 | 0.11% | 2,125 | +83 | +4.07% | 2024-12-31 |
| Xtx Topco Ltd | $3.00 | 0.07% | 1,467 | +1,467 | New | 2024-12-31 |
| Vanguard Group Inc | $2.00 | 0.06% | 1,213 | 0 | 0% | 2024-12-31 |
| Citadel Advisors Llc | $2.00 | 0.05% | 1,001 | +151 | +17.77% | 2024-12-31 |
| Two Sigma Investments, Lp | $1.00 | 0.04% | 810 | -82 | -9.19% | 2024-12-31 |
| Jane Street Group, Llc | $1.00 | 0.04% | 721 | +721 | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.